Please login to the form below

Not currently logged in
Email:
Password:

Dr Reddy's in stroke compound supply deal with Sygnis

Dr Reddy's signs an exclusive 10-year agreement with Germany-based Sygnis Pharma for the supply of an ingredient for stroke and other neurodegenrative disorders

Indian pharmaceutical company Dr Reddy's Laboratories has signed an exclusive 10-year agreement with Germany-based Sygnis Pharma for the supply of an ingredient used in the treatment of stroke and other neurodegenrative disorders.

The active ingredient is biological molecule AX200, which is being developed by Sygnis. The company successfully completed phase IIa clinical trials of the compound in September 2007, which demonstrated safety and efficacy in patients with acute stroke.

Sygnis plans to begin phase IIb trial in H2 2008. The study will be an efficacy trial in acute stroke. AX200 is the most advanced product in Sygnis' portfolio.

Cartikeya Reddy, head of biologics, at Dr Reddy's, said: "Our strategic decision to exclusively produce a biological molecule for a partner is a first in the history of Dr Reddy's and fits very well within our custom pharmaceutical services' business model. We are very optimistic that AX200 will continue to show real potential in the treatment of acute stroke with the potential to be used in the treatment of other degenerative neurological diseases."

30th September 2008

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...
Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...